Skip to main content

Advertisement

Table 2 Mean and SEM values and control adjusted changes for the apolipoproteins ApoB48, ApoC3 and ApoE in serum from the NHPs at baseline and during treatment with the omega-3 rich phospholipid preparation. Dose levels of the administered phospholipids, EPA, DHA and choline are given at the end of the table

From: Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia

Parameter Group Value Baseline Week after start of treatment
1 2 3 4 5 6 7 8 9 10 11 12
ApoB48 (mg/dL) Control Mean 1.84 1.86 1.96 1.77 1.84 1.84 1.97 1.96 1.84 2.00 1.95 1.81 1.93
SEM 0.06 0.05 0.04 0.17 0.12 0.20 0.06 0.07 0.15 0.05 0.08 0.12 0.16
Treated Mean 2.19 2.42 2.17 2.23 2.37 2.25 2.39 2.42 2.27 2.47 2.22 2.61 2.60
SEM 0.21 0.12 0.31 0.05 0.30 0.19 0.31 0.20 0.15 0.07 0.37 0.15 0.10
Control adjusteda - 10 −8 7 8 3 1 4 4 5 −7 22 15
ApoC3 (ng/mL) Control Mean 50.7 62.3 42.5 37.0 40.9 46.2 48.2 39.9 56.9 44.2 28.9 42.2 38.0
SEM 14.5 10.1 3.17 5.40 10.9 15.1 12.0 17.9 18.3 11.4 11.9 17.9 20.4
Treated Mean 45.8 33.6 31.3 21.2 21.4 18.7 18.2 13.4 40.7 28.0 30.2 12.5 14.1
SEM 21.9 20.0 18.7 13.2 13.8 10.5 7.70 10.9 21.0 13.4 21.7 4.85 5.42
Control adjusteda - −71 −34 −40 −44 −57 −56 −51 −26 −34 −1 −45 −31
ApoE (ng/mL) Control Mean 1.06 1.63 1.20 1.23 1.26 1.99 1.15 1.13 1.36 1.36 1.29 1.59 1.32
SEM 0.12 0.24 0.19 0.27 0.07 0.40 0.18 0.10 0.19 0.09 0.17 0.15 0.05
Treated Mean 1.68 1.84 1.72 1.44 2.12 2.37 1.95 2.72 1.73 2.61 2.88 2.41 2.67
SEM 0.19 0.34 0.27 0.14 0.28 0.62 0.36 0.57 0.30 0.62 0.99 0.50 0.65
Control adjusteda 0 −42 −10 −30 6 −46 10 54 −25 23 70 4 29
Dose (mg phospholipids/kg bw/day) 50 150 450
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.0/16.4 84.1/49.3
Dose (mg choline/kg bw/day) 5.83 17.50 52.50
  1. a % change of treated group relative to control group